Cumulatively, these data suggest that particularly targeting HR through ATR inhibition is able to sensitise HPV-negative HNSCC cells to IR, but which requires further validation in multiple cell lines in vitro, as well as demonstrating the impact of this strategy in appropriate in vivo models. Here, ATR is linked to head and neck squamous cell carcinoma.